BAJAJ BROKING
Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the US for treating autoimmune diseases. Approved by the FDA in December 2024, YESINTEK will be available in multiple formulations. Biocon share price ended at ₹321.30, down 0.23% on the BSE.
Biocon Biologics, a subsidiary of Biocon Ltd, has officially launched YESINTEK (ustekinumab-kfce) in the US market, making it one of the first biosimilars to Stelara. The biosimilar is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a more affordable treatment option for patients with chronic autoimmune conditions. The approval from the US Food and Drug Administration (FDA) was granted in December 2024.
Also read: NTPC & NTPC Green Energy to Invest ₹2 Lakh Crore in Madhya Pradesh
Biocon Biologics introduces YESINTEK in the US, a biosimilar alternative to Stelara.
It is approved for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Available in multiple formulations, including 45 mg/0.5 mL PFS and 130 mg/26 mL vial.
FDA approved YESINTEK in December 2024, confirming its similarity to Stelara.
Biocon share price closed at ₹321.30 on BSE, down 0.23%.
Also read: Govt Seeks Merchant Bankers for PSU Stake Sale in Banks & Financial Firms
YESINTEK’s launch in the US expands treatment accessibility for patients suffering from autoimmune diseases. The biosimilar, a monoclonal antibody, disrupts IL-12 and IL-23 mediated signaling, essential in immune-mediated conditions. Clinical trials demonstrated comparable efficacy, safety, and immunogenicity profiles to Stelara, supporting its FDA approval.
YESINTEK will be available in the same formulations as Stelara, ensuring seamless transition for healthcare providers and patients. Additionally, a patient assistance programme has been introduced, offering benefits verification, copay support, and financial assistance, with eligible patients paying as little as $0 under the scheme.
Formulation | Dosage |
Pre-Filled Syringe (PFS) | 45 mg/0.5 mL |
Pre-Filled Syringe (PFS) | 90 mg/mL |
Vial | 45 mg/0.5 mL |
Vial | 130 mg/26 mL |
Following the announcement, Biocon share price declined slightly, closing at ₹321.30 on BSE, reflecting a 0.23% dip. Investors are closely monitoring the biosimilar’s market reception, as its successful uptake could impact Biocon’s revenue and market positioning in the biologics segment.
Biocon Biologics’ launch of YESINTEK strengthens its biosimilar portfolio and reinforces its commitment to expanding affordable treatment options in the US. As one of the first Stelara biosimilars in the market, YESINTEK could drive competition, benefiting patients and healthcare providers alike. The industry will be watching closely for market adoption trends and future biosimilar launches from Biocon.
Also read: ONGC Approves ₹1,200 Crore Investment in ONGC Green for PTC Energy Buy
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading